Alastair Garfield insider trades: Rhythm Pharmaceuticals (RYTM) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Alastair reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | RYTM | ↓ Sell | 7,763 | $117.57 | $913K | Direct | Aug 17, 2026 (4d) |
| Jul 2, 2025 | RYTM | ↓ Sell | 1,319 | $64.81 | $85K | Direct | Jul 3, 2025 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other RYTM insiders
Open-market trades in the last 12 months
About Alastair Garfield's insider trades
Alastair Garfield is Chief Scientific Officer at Rhythm Pharmaceuticals (RYTM). Since Jul 2, 2025, Alastair has reported no open-market purchases and 2 sales worth $998K on SEC Form 4. In the last 12 months: 1 sale ($913K).
Their filings also include option exercises (3 filings), grants and awards (3 filings), shares withheld for taxes (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every RYTM insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.